Pfizer (PFE) Cash from Investing Activities (2009 - 2026)

Pfizer (PFE) has 18 years of Cash from Investing Activities data on file, last reported at $785.0 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $785.0 million, down 76.02% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.8 billion (down 127.66% YoY), and the FY2025 annual result was -$1.4 billion, down 150.94% from the prior year.
• Cash from Investing Activities climbed to $785.0 million in Q1 2026 per PFE's latest filing, from -$6.1 billion in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $4.6 billion in Q2 2024 and troughed at -$25.5 billion in Q3 2023.
• A 5-year average of -$3.0 billion and a median of $785.0 million in 2026 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities surged 484.66% in 2023, then slumped 156.84% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at -$11.4 billion in 2022, then advanced by 3.31% to -$11.0 billion in 2023, then surged by 138.88% to $4.3 billion in 2024, then slumped by 243.77% to -$6.1 billion in 2025, then soared by 112.77% to $785.0 million in 2026.
• Business Quant data shows PFE's Cash from Investing Activities at $785.0 million in Q1 2026, -$6.1 billion in Q4 2025, and -$2.4 billion in Q3 2025.